Kestra Medical Technologies Ltd (KMTS) FinancialsKMTSKestra Medical Technologies Ltd

Evaluating the bottom line, Kestra Medical Technologies, Ltd. maintains a gross margin of 56.50%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -121.59%, while the net margin is -142.35%. These profitability ratios, combined with a Return on Equity (ROE) of -73.74%, provide a clear picture of how effectively KMTS converts its operational activities into shareholder value.

In the context of the broader market, KMTS competes directly with industry leaders such as ATEC and NVCR. With a market capitalization of $1.75B, it holds a leading position in the sector. When comparing efficiency, KMTS's gross margin of 56.50% stands against ATEC's 70.34% and NVCR's 77.61%. Such benchmarking helps identify whether Kestra Medical Technologies, Ltd. is trading at a premium or discount relative to its financial performance.

The company has shown strong revenue growth, with total revenue reaching $30.97 million in Q1 2027, marking a 60% increase year-over-year. The gross margin has also improved significantly, reaching 56.5%.